Greer Labs debuts Oralair for the treatment of grass pollen allergy in USA

USA-based allergy immunotherapy products and services specialist Greer Laboratories today announced the launch and commercial availability of Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract) sublingual allergy immunotherapy tablet.

Greer, which was acquired by Switzerland-based Ares Life Sciences last year (The Pharma Letter March 8), acquired US rights to Oralair from French allergy specialists Stallergenes (Euronext Paris: GENP) last year, I a deal involving $120 million in upfront and milestone payments by the US firm (TPL October 31, 2013).

Oralair is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for any of the five grass species contained in this product. Oralair was approved by the US Food and Drug Administration last month for use in persons 10 through 65 years of age (TPL April 2). It is not indicated for the immediate relief of allergy symptoms.